CYTK
Cytokinetics, Incorporated$70.25+0.98 (+1.42%)Prev Close$69.27·MCap$8.52B·P/E—·Vol805.1K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
80
$36.55M
◆
Net Activity
Net Seller
$36.55M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Cytokinetics, Incorporated (CYTK) has been exclusively selling, with 0 insider purchases totaling $0.00 and 80 insider sales totaling $36.55M. The most recent insider transaction was by Malik Fady Ibraham (officer: EVP Research & Development), who sold $237.9K worth of shares on Jun 9, 2026. Cytokinetics, Incorporated operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $8.52B.
CYTK Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 3,500 | $67.98 | $237.9K | 153,902 |
| Jun 1, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $74.08 | $370.4K | 15,784 |
| Jun 1, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 15,000 | $74.08 | $1.11M | 58,555 |
| Jun 1, 2026 | Kaye Edward M. MD | director | Sell | 2,933 | $76.09 | $223.2K | 10,283 |
| May 28, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 7,500 | $77.21 | $579.1K | 392,830 |
| May 20, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 3,500 | $75.69 | $264.9K | 153,902 |
| May 14, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 7,500 | $77.92 | $584.4K | 400,330 |
| May 5, 2026 | Lee Sung | officer: EVP, Chief Financial Officer | Sell | 23,906 | $76.87 | $1.84M | 63,221-27% |
| May 5, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 11,333 | $77.25 | $875.5K | 58,555 |
| May 5, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 3,500 | $77.37 | $270.8K | 153,902 |
| May 5, 2026 | HENDERSON JOHN T | director | Sell | 20,000 | $75.97 | $1.52M | 75,237 |
| May 5, 2026 | WIERENGA WENDELL | director | Sell | 4,032 | $75.00 | $302.4K | 32,637 |
| May 4, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 15,857 | $65.00 | $1.03M | 58,555 |
| Apr 30, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 15,000 | $63.26 | $948.9K | 58,555 |
| Apr 29, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 7,500 | $59.62 | $447.1K | 407,830 |
| Apr 21, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 3,500 | $65.69 | $229.9K | 153,902 |
| Apr 15, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 7,500 | $65.38 | $490.4K | 415,330 |
| Apr 15, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 7,449 | $66.02 | $491.8K | 58,555 |
| Apr 8, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 4,500 | $65.11 | $293.0K | 153,902 |
| Apr 1, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 7,500 | $66.63 | $499.7K | 422,830 |
| Mar 31, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 3,639 | $65.00 | $236.5K | 66,004 |
| Mar 18, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 36,601 | $62.15 | $2.27M | 454,258 |
| Mar 18, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 10,472 | $62.14 | $650.7K | 78,185 |
| Mar 18, 2026 | Lee Sung | officer: EVP, Chief Financial Officer | Sell | 4,935 | $62.15 | $306.7K | 87,127 |
| Mar 18, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 12,033 | $62.15 | $747.9K | 158,299 |
| Mar 16, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 1,709 | $61.03 | $104.3K | 46,149 |
| Mar 10, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 7,931 | $60.72 | $481.6K | 391,673 |
| Mar 10, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 2,582 | $60.72 | $156.8K | 47,858 |
| Mar 10, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 2,907 | $60.72 | $176.5K | 138,629 |
| Mar 2, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 886 | $61.62 | $54.6K | 50,440 |
| Mar 2, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $61.21 | $306.1K | 17,933 |
| Feb 5, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $61.93 | $929.0K | 0 |
| Feb 2, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 886 | $62.10 | $55.0K | 0 |
| Jan 5, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $60.28 | $904.2K | 0 |
| Jan 2, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,798 | $62.62 | $112.6K | 0 |
| Dec 29, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,809 | $62.44 | $113.0K | 0 |
| Dec 22, 2025 | Blum Robert I | President & CEO | Sell | 33,361 | $67.70 | $2.26M | 0 |
| Dec 22, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 675 | $62.72 | $42.3K | 0 |
| Dec 22, 2025 | Lee Sung | EVP, Chief Financial Officer | Sell | 805 | $62.72 | $50.5K | 0 |
| Dec 22, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | 1,016 | $62.72 | $63.7K | 0 |
| Dec 22, 2025 | WIERENGA WENDELL | Director | Sell | 20,000 | $66.14 | $1.32M | 0 |
| Dec 16, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $61.24 | $134.7K | 0 |
| Dec 8, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,042 | $65.96 | $68.7K | 0 |
| Dec 5, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 52,486 | $65.95 | $3.46M | 0 |
| Dec 3, 2025 | Blum Robert I | President & CEO | Sell | 5,930 | $65.02 | $385.6K | 0 |
| Dec 3, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,368 | $65.02 | $88.9K | 0 |
| Dec 3, 2025 | Lee Sung | EVP, Chief Financial Officer | Sell | 1,560 | $65.02 | $101.4K | 0 |
| Dec 3, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | 2,058 | $65.02 | $133.8K | 0 |
| Dec 2, 2025 | HENDERSON JOHN T | Director | Sell | 8,750 | $63.90 | $559.1K | 0 |
| Dec 2, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $63.89 | $140.6K | 0 |
Showing 1–50 of 358
1 / 8
...
CYTK Insider Buying Activity
The following table shows recent insider purchases of Cytokinetics, Incorporated (CYTK) stock reported via SEC Form 4 filings.
No insider buying activity found for CYTK in the last 12 months.
CYTK Insider Selling Activity
The following table shows recent insider sales of Cytokinetics, Incorporated (CYTK) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 3,500 | $67.98 | $237.9K | 153,902 |
| Jun 1, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $74.08 | $370.4K | 15,784 |
| Jun 1, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 15,000 | $74.08 | $1.11M | 58,555 |
| Jun 1, 2026 | Kaye Edward M. MD | director | Sell | 2,933 | $76.09 | $223.2K | 10,283 |
| May 28, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 7,500 | $77.21 | $579.1K | 392,830 |
| May 20, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 3,500 | $75.69 | $264.9K | 153,902 |
| May 14, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 7,500 | $77.92 | $584.4K | 400,330 |
| May 5, 2026 | Lee Sung | officer: EVP, Chief Financial Officer | Sell | 23,906 | $76.87 | $1.84M | 63,221-27% |
| May 5, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 11,333 | $77.25 | $875.5K | 58,555 |
| May 5, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 3,500 | $77.37 | $270.8K | 153,902 |
| May 5, 2026 | HENDERSON JOHN T | director | Sell | 20,000 | $75.97 | $1.52M | 75,237 |
| May 5, 2026 | WIERENGA WENDELL | director | Sell | 4,032 | $75.00 | $302.4K | 32,637 |
| May 4, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 15,857 | $65.00 | $1.03M | 58,555 |
| Apr 30, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 15,000 | $63.26 | $948.9K | 58,555 |
| Apr 29, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 7,500 | $59.62 | $447.1K | 407,830 |
| Apr 21, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 3,500 | $65.69 | $229.9K | 153,902 |
| Apr 15, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 7,500 | $65.38 | $490.4K | 415,330 |
| Apr 15, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 7,449 | $66.02 | $491.8K | 58,555 |
| Apr 8, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 4,500 | $65.11 | $293.0K | 153,902 |
| Apr 1, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 7,500 | $66.63 | $499.7K | 422,830 |
| Mar 31, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 3,639 | $65.00 | $236.5K | 66,004 |
| Mar 18, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 36,601 | $62.15 | $2.27M | 454,258 |
| Mar 18, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 10,472 | $62.14 | $650.7K | 78,185 |
| Mar 18, 2026 | Lee Sung | officer: EVP, Chief Financial Officer | Sell | 4,935 | $62.15 | $306.7K | 87,127 |
| Mar 18, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 12,033 | $62.15 | $747.9K | 158,299 |
| Mar 16, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 1,709 | $61.03 | $104.3K | 46,149 |
| Mar 10, 2026 | Blum Robert I | director, officer: President & CEO | Sell | 7,931 | $60.72 | $481.6K | 391,673 |
| Mar 10, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 2,582 | $60.72 | $156.8K | 47,858 |
| Mar 10, 2026 | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 2,907 | $60.72 | $176.5K | 138,629 |
| Mar 2, 2026 | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 886 | $61.62 | $54.6K | 50,440 |
| Mar 2, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $61.21 | $306.1K | 17,933 |
| Feb 5, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $61.93 | $929.0K | 0 |
| Feb 2, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 886 | $62.10 | $55.0K | 0 |
| Jan 5, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $60.28 | $904.2K | 0 |
| Jan 2, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,798 | $62.62 | $112.6K | 0 |
| Dec 29, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,809 | $62.44 | $113.0K | 0 |
| Dec 22, 2025 | Blum Robert I | President & CEO | Sell | 33,361 | $67.70 | $2.26M | 0 |
| Dec 22, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 675 | $62.72 | $42.3K | 0 |
| Dec 22, 2025 | Lee Sung | EVP, Chief Financial Officer | Sell | 805 | $62.72 | $50.5K | 0 |
| Dec 22, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | 1,016 | $62.72 | $63.7K | 0 |
| Dec 22, 2025 | WIERENGA WENDELL | Director | Sell | 20,000 | $66.14 | $1.32M | 0 |
| Dec 16, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $61.24 | $134.7K | 0 |
| Dec 8, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,042 | $65.96 | $68.7K | 0 |
| Dec 5, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 52,486 | $65.95 | $3.46M | 0 |
| Dec 3, 2025 | Blum Robert I | President & CEO | Sell | 5,930 | $65.02 | $385.6K | 0 |
| Dec 3, 2025 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,368 | $65.02 | $88.9K | 0 |
| Dec 3, 2025 | Lee Sung | EVP, Chief Financial Officer | Sell | 1,560 | $65.02 | $101.4K | 0 |
| Dec 3, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | 2,058 | $65.02 | $133.8K | 0 |
| Dec 2, 2025 | HENDERSON JOHN T | Director | Sell | 8,750 | $63.90 | $559.1K | 0 |
| Dec 2, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $63.89 | $140.6K | 0 |
CYTK Insiders
Similar Stocks to CYTK
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B